Nanotechnology Interventions in Chronic Respiratory Diseases: Focus on COPD- A Review

Abhishek  Kumar; Naneshwari Kanhaiyalal   Rahangdale

doi:10.22270/jddt.v16i9.8011

Authors

Abhishek Kumar Faculty of Medical, Paramedical and Allied Health Sciences, Department of Pharmacy, Jagannath University, Jaipur, 303901, Rajasthan, India. https://orcid.org/0009-0000-4725-4436
Naneshwari Kanhaiyalal Rahangdale Department of Pharmacy, Imperial College of Pharmacy, Tiroda (DTE CODE-4750, MSBTE-32595), India.

Abstract

Chronic obstructive pulmonary disease (COPD) refers to a progressive respiratory disease associated with airflow obstruction, chronic inflammation, oxidative stress, and irreversible damage to lung tissue. While conventional treatment regimens offer symptomatic relief, they are hampered by poor targeting of the lungs, systemic side effects, and low efficacy. Nanotechnology offers great potential in the enhancement of drug delivery, improvement of efficacy, and diagnosis of COPD. This paper discusses the current progress in nanotechnology-based interventions for COPD through novel carriers, targeted drug delivery, diagnosis, regenerative therapy, and translational barriers. Literature Review A literature review was carried out by collecting relevant scholarly literature from the PubMed, Scopus, Web of Science, ScienceDirect, and Google Scholar databases. Studies discussing nanotechnology-based therapeutic and diagnostic strategies for COPD were selected and critically analyzed. Present literature proves that nanotechnology-based drug delivery methods increase efficiency of pulmonary drug delivery, increase therapeutic efficiency, control drug delivery, and minimize toxicity. Newer applications of nanotechnology in molecular diagnostics, genetic delivery, and nanoregenerative medicine are some more areas where application of nanotechnology could revolutionize management of patients with COPD, but not much research has been done yet in this area. It is clear that nanotechnology holds great promise in making COPD treatment more effective and personalized. But further research is needed on safety aspects, manufacturing, regulations, etc.

Keywords: Chronic obstructive pulmonary disease (COPD); Nanotechnology; Nanocarriers; Pulmonary drug delivery; Targeted therapy.

Keywords:

Chronic obstructive pulmonary disease (COPD), Nanotechnology, Nanocarriers, Pulmonary drug delivery, Targeted therapy

DOI

https://doi.org/10.22270/jddt.v16i9.8011

Author Biographies

Abhishek Kumar , Faculty of Medical, Paramedical and Allied Health Sciences, Department of Pharmacy, Jagannath University, Jaipur, 303901, Rajasthan, India.

Faculty of Medical, Paramedical and Allied Health Sciences, Department of Pharmacy, Jagannath University, Jaipur, 303901, Rajasthan, India.

Naneshwari Kanhaiyalal Rahangdale , Department of Pharmacy, Imperial College of Pharmacy, Tiroda (DTE CODE-4750, MSBTE-32595), India.

Department of Pharmacy, Imperial College of Pharmacy, Tiroda (DTE CODE-4750, MSBTE-32595), India.

References

1. Abd-Rabou, A. A., and Ahmed, H. H. (2019). Bevacizumab and CCR2 inhibitor nanoparticles induce cytotoxicity-mediated apoptosis in doxorubicin-treated hepatic and non-small lung cancer cells. Asian Pac. J. Cancer Prev. APJCP 20, 2225–2238. doi:10.31557/APJCP.2019.20.7.2225

2. Adali, M. B., Barresi, A. A., Boccardo, G., and Pisano, R. (2020). Spray freeze-drying as a solution to continuous manufacturing of pharmaceutical products in bulk. Processes 8, 709. doi:10.3390/pr8060709 Ahmad, A. (2022). Pharmacological strategies and recent advancement in nano-drug delivery for targeting asthma. Life 12, 596. doi:10.3390/life12040596

3. Akbarzadeh, I., Farid, M., Javidfar, M., Zabet, N., Shokoohian, B., Arki, M. K., et al. (2022). The optimized formulation of tamoxifen-loaded niosomes efficiently induced apoptosis and cell cycle arrest in breast cancer cells. AAPS PharmSciTech 23, 57–13. doi:10.1208/s12249-022-02212-0

4. Akhter, M. H., Rizwanullah, M., Ahmad, J., Ahsan, M. J., Mujtaba, M. A., and Amin, S. (2018). Nanocarriers in advanced drug targeting: Setting novel paradigm in cancer therapeutics. Artif. cells, nanomedicine, Biotechnol. 46, 873–884. doi:10.1080/21691401.2017.1366333

5. Al-Otaibi, A. M., Al-Gebaly, A. S., Almeer, R., Albasher, G., Al-Qahtani, W. S., and Abdel Moneim, A. E. (2022). Potential of green-synthesized selenium nanoparticles using apigenin in human breast cancer MCF-7 cells. Environ. Sci. Pollut. Res. 29, 47539–47548. doi:10.1007/s11356-022-19166-2

6. Alhawmdeh, M., Isreb, M., Aziz, A., Jacob, B. K., Anderson, D., and Najafzadeh, M. (2021). Interferon-γ liposome: A new system to improve drug delivery in the treatment of lung cancer. ERJ Open Res. 7, 00555. doi:10.1183/23120541.00555-2020

7. Arabzadeh E., Shirvani H., Masjedi M.R., Ghanei M., Hofmeister M., Rostamkhani F. Treadmill exercise with nanoselenium supplementation affects the expression of Irisin/FNDC5 and semaphorin 3A in rats exposed to cigarette smoke extract. 3 Biotech. 2024;14:4. doi: 10.1007/s13205-023-03849-9. [DOI] [PMC free article] [PubMed] [Google Scholar]

8. Liu X., Chen Z. The pathophysiological role of mitochondrial oxidative stress in lung diseases. J. Transl. Med. 2017;15:207. doi: 10.1186/s12967-017-1306-5. [DOI] [PMC free article] [PubMed] [Google Scholar]

9. Soulitzis N., Neofytou E., Psarrou M., Anagnostis A., Tavernarakis N., Siafakas N., Tzortzaki E.G. Downregulation of lung mitochondrial prohibitin in COPD. Respir. Med. 2012;6:954–961. doi: 10.1016/j.rmed.2012.03.019. [DOI] [PubMed] [Google Scholar]

10. Bushueva, T. V., Panov, V. G., Minigalieva, I. A., Privalova, L. I., Vedernikova, M. S., Gurvich, V. B., et al. (2023). Dose dependence of the separate and combined impact of copper-oxide and selenium-oxide nanoparticles on oxygen consumption by cells in vitro with or without the background action of some modulators of the mitochondrial respiratory function. Dose-Response 21, 155932582211066. doi:10. 1177/15593258221106612

11. Russo C., Valle M.S., Casabona A., Spicuzza L., Sambataro G., Malaguarnera L. Vitamin D Impacts on Skeletal Muscle Dysfunction in Patients with COPD Promoting Mitochondrial Health. Biomedicines. 2022;10:898. doi: 10.3390/biomedicines10040898. [DOI] [PMC free article] [PubMed] [Google Scholar]

12. Pachani S, Shah TM. Formulation of paclitaxel-encapsulated polymeric micelles for targeted breast cancer therapy. J Popul Ther Clin Pharmacol. 2021;28(2):936–951. doi:10.53555/m318xt37. Journal of Population Therapeutics

13. Wu J., Zhai T., Sun J., Yu Q., Feng Y., Li R., Wang H., Ouyang Q., Yang T., Zhan Q., et al. Corrigendum to Mucus-permeable polymyxin B-hyaluronic acid/poly (lactic-co-glycolic acid) nanoparticle platform for the nebulized treatment of lung infections. J. Colloid Interface Sci. 2023;624:307–319. doi: 10.1016/j.jcis.2022.05.121. Erratum in J. Colloid Interface Sci. 2023, 629 Pt A, 882–883. [DOI] [PubMed] [Google Scholar]

14. Beck-Broichsitter M., Gauss J., Gessler T., Seeger W., Kissel T., Schmehl T. Pulmonary targeting with biodegradable salbutamol-loaded nanoparticles. J. Aerosol Med. Pulm. Drug Deliv. 2010;23:47–57. doi: 10.1089/jamp.2009.0759. [DOI] [PubMed] [Google Scholar]

15. Chikuma K., Arima K., Asaba Y., Kubota R., Asayama S., Sato K., Kawakami H. The potential of lipid-polymer nanoparticles as epigenetic and ROS control approaches for COPD. Free Radic. Res. 2020;54:829–840. doi: 10.1080/10715762.2019.1696965. [DOI] [PubMed] [Google Scholar]

16. Chen, C.-T., Salunke, S., Wei, T.-T., Tang, Y.-A., and Wang, Y.-C. (2021). Fluorescent nanohybrids from ZnS/CdSe quantum dots functionalized with triantennary, N-Hydroxy-p-(4-arylbutanamido)benzamide/Gallamide dendrons that act as inhibitors of histone deacetylase for lung cancer. ACS Appl. Bio Mater. 4, 2475–2489. doi:10.1021/acsabm.0c01438

17. Saghir S.A., Al-Gabri N.A., Khafaga A.F., El-Shaer N.H., Alhumaidh K.A., Elsadek M.F., Ahmed B.M., Alkhawtani D.M., Abd El-Hack M.E. Thymoquinone-PLGA-PVA nanoparticles ameliorate bleomycin-induced pulmonary fibrosis in rats via regulation of inflammatory cytokines and iNOS signaling. Animals. 2019;9:951. doi: 10.3390/ani9110951. [DOI] [PMC free article] [PubMed] [Google Scholar]

18. Cedrowska, E., Pruszynski, M., Gaweda, W., Zuk, M., Krysinski, P., Bruchertseifer, F., et al. (2020). Trastuzumab conjugated superparamagnetic iron oxide nanoparticles labeled with (225)Ac as a perspective tool for combined alpha-radioimmunotherapy and magnetic hyperthermia of HER2-positive breast cancer. Molecules 25, 1025. doi:10. 3390/molecules25051025

19. Wyszogrodzka-Gaweł G., Dorożyński P., Giovagnoli S., Strzempek W., Pesta E., Węglarz W.P., Gil B., Menaszek E., Kulinowski P. An inhalable theranostic system for local tuberculosis treatment containing an isoniazid loaded metal organic framework Fe-MIL-101-NH2-from raw MOF to drug delivery system. Pharmaceutics. 2019;11:687. doi: 10.3390/pharmaceutics11120687. [DOI] [PMC free article] [PubMed] [Google Scholar]

20. El-Sherbiny I.M., Smyth H.D. Controlled release pulmonary administration of curcumin using swellable biocompatible microparticles. Mol. Pharm. 2012;9:269–280. doi: 10.1021/mp200351y. [DOI] [PMC free article] [PubMed] [Google Scholar]

21. Zhou, L., Li, P., Zhang, M., Han, B., Chu, C., Su, X., et al. (2020). Carbon black nanoparticles induce pulmonary fibrosis through NLRP3 inflammasome pathway modulated by miR-96 targeted FOXO3a. Chemosphere 241, 125075. doi:10.1016/j. chemosphere.2019.125075

22. Bodas M., Pehote G., Silverberg D., Gulbins E., Vij N. Autophagy augmentation alleviates cigarette smoke-induced CFTR-dysfunction, ceramide-accumulation and COPD-emphysema pathogenesis. Free Radic. Biol. Med. 2019;131:81–97. doi: 10.1016/j.freeradbiomed.2018.11.023. [DOI] [PubMed] [Google Scholar]

23. Shukla, K., S, V., Mishra, R., Sahoo, S., Saxena, G., Shah, T. M., Rahaman, A., Chawra, H. S., & Pal, R. (2026). Nanoparticles (NPs) as a Cutting-Edge Therapeutic Strategy and Their Current Status in Tuberculosis (TB): A Comprehensive Review. Recent advances in drug delivery and formulation, 10.2174/0126673878403646251209194351. Advance online publication. https://doi.org/10.2174/0126673878403646251209194351

24. Konduri K.S., Nandedkar S., Düzgünes N., Suzara V., Artwohl J., Bunte R., Gangadharam P.R. Efficacy of liposomal budesonide in experimental asthma. J. Allergy Clin. Immunol. 2003;111:321–327. doi: 10.1067/mai.2003.104. [DOI] [PubMed] [Google Scholar]

25. Ahmad T., Mabalirajan U., Ghosh B., Agrawal A. Altered asymmetric dimethyl arginine metabolism in allergically inflamed mouse lungs. Am. J. Respir. Cell Mol. Biol. 2010;42:3–8. doi: 10.1165/rcmb.2009-0137RC. [DOI] [PubMed] [Google Scholar]

26. Mosgoeller W., Prassl R., Zimmer A. Nanoparticle-mediated treatment of pulmonary arterial hypertension. Methods Enzymol. 2012;508:325–354. doi: 10.1016/B978-0-12-391860-4.00017-3. [DOI] [PubMed] [Google Scholar]

27. Paturi D., Patel M., Mitra R., Mitra A.K. Pulmonary Nanomedicine. 1st ed. Jenny Stanford Publishing; Singapore: 2012. Nasal and pulmonary delivery of macromolecules to treat respiratory and nonrespiratory diseases. [Google Scholar]

28. Saari M., Vidgren M.T., Koskinen M.O., Turjanmaa V.M., Nieminen M.M. Pulmonary distribution and clearance of two beclomethasone liposome formulations in healthy volunteers. Int. J. Pharm. 1999;181:1–9. doi: 10.1016/S0378-5173(98)00398-6. [DOI] [PubMed] [Google Scholar]

29. Suntres Z.E. Liposomal Antioxidants for Protection against Oxidant-Induced Damage. J. Toxicol. 2011;2011:152474. doi: 10.1155/2011/152474. [DOI] [PMC free article] [PubMed] [Google Scholar]

30. Hoesel L.M., Flierl M.A., Niederbichler A.D., Rittirsch D., McClintock S.D., Reuben J.S., Pianko M.J., Stone W., Yang H., Smith M., et al. Ability of antioxidant liposomes to prevent acute and progressive pulmonary injury. Antioxid. Redox Signal. 2008;10:963–972. doi: 10.1089/ars.2007.1878. [DOI] [PubMed] [Google Scholar]

31. Mukhopadhyay S., Mukherjee S., Ray B.K., Ray A., Stone W.L., Das S.K. Antioxidant liposomes protect against CEES-induced lung injury by decreasing SAF-1/MAZ-mediated inflammation in the guinea pig lung. J. Biochem. Mol. Toxicol. 2010;24:187–194. doi: 10.1002/jbt.20329. [DOI] [PubMed] [Google Scholar]

32. Manconi M., Manca M.L., Valenti D., Escribano E., Hillaireau H., Fadda A.M., Fattal E. Chitosan and hyaluronan coated liposomes for pulmonary administration of curcumin. Int. J. Pharm. 2017;525:203–210. doi: 10.1016/j.ijpharm.2017.04.044. [DOI] [PubMed] [Google Scholar]

33. Dave P, Raval B, Dudhat K. Cubosomes: Next-generation nanocarriers for versatile drug delivery system for cancer therapy and other applications. Biomedical Materials & Devices. 2026 Jun;4(2):1819-50.

34. De Rubis G., Paudel K.R., Manandhar B., Singh S.K., Gupta G., Malik R., Shen J., Chami A., MacLoughlin R., Chellappan D.K., et al. Agarwood Oil Nanoemulsion Attenuates Cigarette Smoke-Induced Inflammation and Oxidative Stress Markers in BCi-NS1.1 Airway Epithelial Cells. Nutrients. 2023;15:1019. doi: 10.3390/nu15041019. [DOI] [PMC free article] [PubMed] [Google Scholar]

35. Amani A., York P., Chrystyn H., Clark B.J. Evaluation of a nanoemulsion-based formulation for respiratory delivery of budesonide by nebulizers. Aaps PharmSciTech. 2010;11:1147–1151. doi: 10.1208/s12249-010-9486-9. [DOI] [PMC free article] [PubMed] [Google Scholar]

36. Zhang, M., Li, M., Du, L., Zeng, J., Yao, T., and Jin, Y. (2020b). Paclitaxel-in-liposomein-bacteria for inhalation treatment of primary lung cancer. Int. J. Pharm. 578, 119177. doi:10.1016/j.ijpharm.2020.119177

37. Akinc A., Zumbuehl A., Goldberg M., Leshchiner E.S., Busini V., Hossain N., Bacallado S.A., Nguyen D.N., Fuller J., Alvarez R., et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotechnol. 2008;26:561–569. doi: 10.1038/nbt1402. [DOI] [PMC free article] [PubMed] [Google Scholar]

38. Craparo E.F., Cabibbo M., Scialabba C., Giammona G., Cavallaro G. Inhalable Formulation Based on Lipid-Polymer Hybrid Nanoparticles for the Macrophage Targeted Delivery of Roflumilast. Biomacromolecules. 2022;23:3439–3451. doi: 10.1021/acs.biomac.2c00576. [DOI] [PMC free article] [PubMed] [Google Scholar]

39. Nasr M., Najlah M., D’Emanuele A., Elhissi A. PAMAM dendrimers as aerosol drug nanocarriers for pulmonary delivery via nebulization. Int. J. Pharm. 2014;461:242–250. doi: 10.1016/j.ijpharm.2013.11.023. [DOI] [PubMed] [Google Scholar]

40. Shchepinov M.S., Udalova I.A., Bridgman A.J., Southern E.M. Oligonucleotide dendrimers: Synthesis and use as polylabelled DNA probes. Nucleic Acids Res. 1997;25:4447–4454. doi: 10.1093/nar/25.22.4447. [DOI] [PMC free article] [PubMed] [Google Scholar]

41. Taghavizadeh Yazdi M.E., Qayoomian M., Beigoli S., Boskabady M.H. Recent advances in nanoparticle applications in respiratory disorders:a review. Front. Pharmacol. 2023;14:1059343. doi: 10.3389/fphar.2023.1059343. [DOI] [PMC free article] [PubMed] [Google Scholar]

42. Geiser M., Quaile O., Wenk A., Wigge C., Eigeldinger-Berthou S., Hirn S., Schäffler M., Schleh C., Möller W., Mall M.A., et al. Cellular uptake and localization of inhaled gold nanoparticles in lungs of mice with chronic obstructive pulmonary disease. Part. Fibre Toxicol. 2013;10:19. doi: 10.1186/1743-8977-10-19. [DOI] [PMC free article] [PubMed] [Google Scholar]

43. Anderson C.F., Grimmett M.E., Domalewski C.J., Cui H. Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2020;12:e1586. doi: 10.1002/wnan.1586. [DOI] [PMC free article] [PubMed] [Google Scholar]

44. Niemiec S.M., Hilton S.A., Wallbank A., Azeltine M., Louiselle A.E., Elajaili H., Allawzi A., Xu J., Mattson C., Dewberry L.C., et al. Cerium oxide na-noparticle delivery of microRNA-146a for local treatment of acute lung injury. Nanomedicine. 2021;34:102388. doi: 10.1016/j.nano.2021.102388. [DOI] [PMC free article] [PubMed] [Google Scholar]

45. Yin M., Lei D., Liu Y., Qin T., Gao H., Lv W., Liu Q., Qin L., Jin W., Chen Y., et al. NIR triggered polydopamine coated cerium dioxide nanozyme for ameliorating acute lung injury via enhanced ROS scavenging. J. Nanobiotechnol. 2024;22:321. doi: 10.1186/s12951-024-02570-w. [DOI] [PMC free article] [PubMed] [Google Scholar]

46. Kim W.I., Pak S.W., Lee S.J., Park S.H., Lim J.O., Kim D.I., Shin I.S., Kim S.H., Kim J.C. Copper oxide nanoparticles exacerbate chronic obstructive pulmonary disease by acti-vating the TXNIP-NLRP3 signaling pathway. Part. Fibre Toxicol. 2024;21:46. doi: 10.1186/s12989-024-00608-3. [DOI] [PMC free article] [PubMed] [Google Scholar]

47. Waters R.C., Hochhaus G. Characterization of a dextran-budesonide prodrug for inhalation therapy. Eur. J. Pharm. Sci. 2019;129:58–67. doi: 10.1016/j.ejps.2018.11.038. [DOI] [PubMed] [Google Scholar]

48. Hu Q., Lu Y., Luo Y. Recent advances in dextran-based drug delivery systems: From fabrication strategies to applications. Carbohydr. Polym. 2021;264:117999. doi: 10.1016/j.carbpol.2021.117999. [DOI] [PubMed] [Google Scholar]

49. Wang Z., Gupta S.K., Meenach S.A. Development and physicochemical characterization of acetalated dextran aerosol particle systems for deep lung delivery. Int. J. Pharm. 2017;525:264–274. doi: 10.1016/j.ijpharm.2017.04.052. [DOI] [PMC free article] [PubMed] [Google Scholar]

50. Wang S., Wannasarit S., Figueiredo P., Molinaro G., Ding Y., Correia A., Casettari L., Wiwattanapatapee R., Hirvonen J., Liu D., et al. Intracellular delivery of budesonide and polydopamine Co-loaded in endosomolytic poly (butyl methacrylate-co-methacrylic acid) grafted acetalated dextran for macrophage phenotype switch from M1 to M2. Adv. Ther. 2020;4:2000058. doi: 10.1002/adtp.202000058. [DOI] [Google Scholar]

51. Ferrer M.C., Shuvaev V.V., Zern B.J., Composto R.J., Muzykantov V.R., Eckmann D.M. Icam-1 targeted nanogels loaded with dexamethasone alleviate pulmonary inflammation. PLoS ONE. 2014;9:e102329. doi: 10.1371/journal.pone.0102329. [DOI] [PMC free article] [PubMed] [Google Scholar]

52. Al Faraj A., Shaik A.S., Afzal S., Al Sayed B., Halwani R. MR imaging and targeting of a specific alveolar macrophage subpopulation in LPS-induced COPD animal model using antibody-conjugated magnetic nanoparticles. Int. J. Nanomed. 2014;9:1491–1503. doi: 10.2147/IJN.S59394. [DOI] [PMC free article] [PubMed] [Google Scholar]

53. Zinderman C.E., Landow L., Wise R.P. Anaphylactoid reactions to Dextran 40 and 70: Reports to the United States Food and Drug Administration, 1969 to 2004. J. Vasc. Surg. 2006;43:1004–1009. doi: 10.1016/j.jvs.2006.01.006. [DOI] [PubMed] [Google Scholar]

54. Biesenbach G., Kaiser W., Zazgornik J. Incidence of acute oligoanuric renal failure in dextran 40 treated patients with acute ischemic stroke stage III or IV. Ren. Fail. 1997;19:69–75. doi: 10.3109/08860229709026261. [DOI] [PubMed] [Google Scholar]

55. Zhang L., Valizadeh H., Alipourfard I., Bidares R., Aghebati-Maleki L., Ahmadi M. Epigenetic Modifications and Therapy in Chronic Obstructive Pulmonary Disease (COPD): An Update Review. COPD J. Chronic Obstr. Pulm. Dis. 2020;17:333–342. doi: 10.1080/15412555.2020.1780576. [DOI] [PubMed] [Google Scholar]

56. Donaldson A., Natanek S.A., Lewis A., Man W.D., Hopkinson N.S., Polkey M.I., Kemp P.R. Increased skeletal muscle-specific microRNA in the blood of patients with COPD. Thorax. 2013;68:1140–1149. doi: 10.1136/thoraxjnl-2012-203129. [DOI] [PMC free article] [PubMed] [Google Scholar]

57. Sun Y., An N., Li J., Xia J., Tian Y., Zhao P., Liu X., Huang H., Gao J., Zhang X. miRNA-206 regulates human pulmonary microvascular endothelial cell apoptosis via targeting in chronic obstructive pulmonary disease. J. Cell Biochem. 2019;120:6223–6236. doi: 10.1002/jcb.27910. [DOI] [PubMed] [Google Scholar]

58. Kim J., Kim D.Y., Heo H.R., Choi S.S., Hong S.H., Kim W.J. Role of miRNA-181a-2-3p in cadmium-induced inflammatory responses of human bronchial epithelial cells. J. Thorac. Dis. 2019;11:3055–3069. doi: 10.21037/jtd.2019.07.55. [DOI] [PMC free article] [PubMed] [Google Scholar]

59. Connolly M., Paul R., Farre-Garros R., Natanek S.A., Bloch S., Lee J., Lorenzo J.P., Patel H., Cooper C., Sayer A.A., et al. miR-424-5p reduces ribosomal RNA and protein synthesis in muscle wasting. J. Cachexia Sarcopenia Muscle. 2018;9:400–416. doi: 10.1002/jcsm.12266. [DOI] [PMC free article] [PubMed] [Google Scholar]

60. Jessamine V., Mehndiratta S., De Rubis G., Paudel K.R., Shetty S., Suares D., Chellappan D.K., Oliver B.G., Hansbro P.M., Dua K. The application of nanoparticles as advanced drug delivery systems in Attenuating COPD. Heliyon. 2024;10:e25393. doi: 10.1016/j.heliyon.2024.e25393. [DOI] [PMC free article] [PubMed] [Google Scholar]

61. Taganov K.D., Boldin M.P., Chang K.J., Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl. Acad. Sci. USA. 2006;103:12481–12486. doi: 10.1073/pnas.0605298103. [DOI] [PMC free article] [PubMed] [Google Scholar]

62. Zhao X., Feng J., Zhang L., Li M., Du Y., Li Y., Wu Q., Li G. One functional variant in the 3’-untraslated region of TLR4 is associated with the elevated risk of ventilator-associated pneumonia in the patients with chronic obstructive pulmonary disease. J. Cell. Physiol. 2019;234:18879–18886. doi: 10.1002/jcp.28526. [DOI] [PubMed] [Google Scholar]

63. Sekine Y., Katsura H., Koh E., Hiroshima K., Fujisawa T. Early detection of COPD is important for lung cancer surveillance. Eur. Respir. J. 2012;39:1230–1240. doi: 10.1183/09031936.00126011. [DOI] [PubMed] [Google Scholar]

64. Keller A., Ludwig N., Fehlmann T., Kahraman M., Backes C., Kern F., Vogelmeier C.F., Diener C., Fischer U., Biertz F., et al. Low miR-150-5p and miR-320b Expression Predicts Reduced Survival of COPD Patients. Cells. 2019;8:1162. doi: 10.3390/cells8101162. [DOI] [PMC free article] [PubMed] [Google Scholar]

65. Mohamed A., Pekoz A.Y., Ross K., Hutcheon G.A., Saleem I.Y. Pulmonary delivery of Nanocomposite Microparticles (NCMPs) incorporating miR-146a for treatment of COPD. Int. J. Pharm. 2019;569:118524. doi: 10.1016/j.ijpharm.2019.118524. [DOI] [PubMed] [Google Scholar]